ArticlePituitary2024
Consensus on criteria for acromegaly diagnosis and remission.
Article in Pituitary, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 130 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
130 citing papers in PubMed, 3 syntheses or guidelines pooled it, 162 citations in OpenAlex.
- Clinical characteristics associated with somaticFrontiers in endocrinology · 2026Pooled it
- Impact of pasireotide on lipid and glucose metabolism in patients with acromegaly: a systematic review and meta-analysis.Journal of endocrinological investigation · 2025Pooled it
- Real-world evidence of effectiveness and safety of pasireotide in the treatment of acromegaly: a systematic review and meta-analysis.Reviews in endocrine & metabolic disorders · 2025Pooled it
- Is endoscopic diving technique effective in surgical management of functioning pituitary adenomas? A prospective randomized study.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2025Trial
- Population Pharmacokinetic Analysis of an Octreotide Depot (CAM2029) in the Treatment of Acromegaly.Clinical pharmacokinetics · 2025Trial
- Growth hormone-releasing hormone, growth hormone, and neuroendocrine tumors.Journal of clinical & translational endocrinology · 2026Review
- Endoscopic Transsphenoidal Selective Resection of the Medial Wall of the Cavernous Sinus for the Treatment of Functional Pituitary Adenomas.Journal of neurological surgery. Part B, Skull base · 2026Article
- Predictors of prolonged hypogonadism in men with prolactinomas despite biochemical remission: the role of baseline luteinizing hormone.Journal of endocrinological investigation · 2026Article
- Endoscopic endonasal approach for recurrent or residual pituitary neuroendocrine tumors.Neurosurgical review · 2026Article
- Acromegaly and cardiovascular disease: mechanisms, clinical impact, and evolving management.Endocrine reviews · 2026Review
- Internal validation of THINKERS-PA for outcome prediction after pituitary adenoma radiosurgery.Pituitary · 2026Article
- Thyroid abnormalities in acromegaly in the era of improved disease control: a two-stage study.Journal of endocrinological investigation · 2026Article
- STING expression in pituitary neuroendocrine tumour immune microenvironments.Endocrine-related cancer · 2026Article
- Endoscopic endonasal transcavernous surgery for knosp grade 3-4 growth hormone-secreting pituitary neuroendocrine tumors: surgical outcomes and predictors of biochemical remission.Neurosurgical review · 2026Article
- Beyond biochemical control: factors associated with quality of life in patients with acromegaly.Pituitary · 2026Article
- Soluble alpha-klotho as an adjunct biomarker of disease activity in acromegaly: Added value beyond GH and IGF-1.Pituitary · 2026Article
- Postoperative Pituitary MRI Findings in Acromegaly: A Pictorial Review.Diagnostics (Basel, Switzerland) · 2026Review
- Can acromegaly be controlled in all cases?Journal of neuroendocrinology · 2026Review
- LINAC-based Stereotactic Radiotherapy for Acromegaly: A Single-center Retrospective Cohort.Journal of neurological surgery. Part B, Skull base · 2026Article
- Assessment of nurses' knowledge and awareness of acromegaly in a high-volume tertiary center: a cross-sectional study.Pituitary · 2026Article
70 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
10 authors at 8 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe 14th Acromegaly Consensus Conference was convened to consider biochemical criteria for acromegaly diagnosis and evaluation of therapeutic efficacy.
methodsFifty-six acromegaly experts from 16 countries reviewed and discussed current evidence focused on biochemical assays; criteria for diagnosis and the role of imaging, pathology, and clinical assessments; consequences of diagnostic delay; criteria for remission and recommendations for follow up; and the value of assessment and monitoring in defining disease progression, selecting appropriate treatments, and maximizing patient outcomes.
resultsIn a patient with typical acromegaly features, insulin-like growth factor (IGF)-I > 1.3 times the upper limit of normal for age confirms the diagnosis. Random growth hormone (GH) measured after overnight fasting may be useful for informing prognosis, but is not required for diagnosis. For patients with equivocal results, IGF-I measurements using the same validated assay can be repeated, and oral glucose tolerance testing might also be useful. Although biochemical remission is the primary assessment of treatment outcome, biochemical findings should be interpreted within the clinical context of acromegaly. Follow up assessments should consider biochemical evaluation of treatment effectiveness, imaging studies evaluating residual/recurrent adenoma mass, and clinical signs and symptoms of acromegaly, its complications, and comorbidities. Referral to a multidisciplinary pituitary center should be considered for patients with equivocal biochemical, pathology, or imaging findings at diagnosis, and for patients insufficiently responsive to standard treatment approaches.
conclusionConsensus recommendations highlight new understandings of disordered GH and IGF-I in patients with acromegaly and the importance of expert management for this rare disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.